Influenza Vaccines Market 2018 - Industry Growth: Seqirus Vaccines Limited, GlaxoSmithKline plc, Sanofi, and MedImmmune LLC. Furthermore, companies having products in pipeline includes FluGen, Moderna Therapeutics, Novavax, and BioCryst

The constant mutation in genetic structure of influenza virus results in emergence of new virus, unaffected by currently available influenza vaccines. These continuously evolving virus is expected to be the major restrain for growth of the influenza vaccine market. Moreover, high cost of vaccine development is also expected to hinder market growth over the forecast period.

Rising pipeline product to come up with new vaccine product as a part of key organic strategies by market players. For instance, 2017, Seqirus’s FLAUD, first and only adjuvant-based trivalent influenza vaccine, received MHRA approval against influenza virus in older aged people (adults aged 65 and above). In same year, Seqirus entered in the U.S market with its influenza vaccine portfolio, with over 50 million doses for protection against seasonal influenza of 2017-2018.

Get Exclusive Sample Copy@ https://www.coherentmarketinsights.com/insight/request-sample/1705

Inorganic strategies by the key players:
1 Seqirus Vaccines Limited
2 GlaxoSmithKline plc
3 Sanofi
4 MedImmmune LLC
5 FluGen
6 Moderna Therapeutics
7 Novavax
8 BioCryst

Strategic merger and collaboration by the market players is boosting growth of the 
influenza vaccine market. For instance, in 2015, BioCryst Pharmaceuticals, entered into license agreement with Seqirus Vaccine Limited, under which Seqirus grants worldwide rights to BioCrysts flu Treatment. Moreover, in August 2017, Sanofi acquired Protein Science Corporation. The acquisition added Flubok, the only FDA approved recombinant protein based influenza vaccine to the Sanofi’s product portfolio.

The portfolio includes FLAUD, FLUCELVAX QUADRIVALENT, AFLURIA QUADRIVALENT, AFLURIA, and FLUVIRIN. Moreover, in 2017, FluGen, Inc., received US$ 14.4 million by Department of Defense for evaluating Universal Flu Vaccine, RedeeFlu, of Mismatched Strains. In Sep 2017, Novavax initiating phase1/2 clinical trials for nanoparticle seasonal influenza vaccine in older adults. In April 2018, BiodVax Pharmaceuticals LTD., started enrollment of patients for phase 2 clinical trials for universal flu vaccine candidate, M-001.

Ask Questions to Expertise@ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1705

Detailed Segmentation:

Global Influenza Vaccine Market, By Vaccine Type:
Trivalent Vaccines
Quadrivalent Vaccines
Global Influenza Vaccine Market, By Virus Type:
Influenza Virus A
Influenza Virus B
Global Influenza Vaccine Market, By Age Group:
Pediatrics
Adults

1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Vaccine Type
Market Snippet, By Virus Type
Market Snippet, By Age Group
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Industry Trends
Pipeline Products
Regulatory Scenario
Epidemiology
PEST Analysis
PORTER’S Five Forces

Inquire Before Buying@ https://www.coherentmarketinsights.com/insight/buy-now/1705

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.